Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX/bevacizumab with or without irinotecan for first-line metastatic colorectal cancer
2010-022162-27Phase 2Completed
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Apr 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab, oxaliplatin, irinotecan, fluorouracil and folinic acid in colorectal cancer (CRC) (2 arms), sponsored by Martin Luther University Halle-Wittenberg. Primary endpoint: Progression-free survival rate at 9 months. Started Apr 2011; status: completed.
02
Drugs
bevacizumaboxaliplatinirinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2010-022162-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022162-27.